Related references
Note: Only part of the references are listed.Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
Jessina McGregor
Therapeutics and Clinical Risk Management (2016)
Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America
Thomas M. Hooton et al.
CLINICAL INFECTIOUS DISEASES (2010)
Escherichia coli Sequence Type ST131 as the Major Cause of Serious Multidrug-Resistant E. coli Infections in the United States
James R. Johnson et al.
CLINICAL INFECTIOUS DISEASES (2010)
Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum β-lactamases in outpatient urinary E. coli between 2003 and 2008
Chao Qi et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities
Carl Urban et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Infections with Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Changing Epidemiology and Drug Treatment Choices
Johann D. D. Pitout
DRUGS (2010)
Emerging drugs for bacterial urinary tract infections
Florian M. E. Wagenlehner et al.
EXPERT OPINION ON EMERGING DRUGS (2010)
Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment
Ioannis Katsarolis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation
David E. Nix et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice
Akke Vellinga et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrump-β-lactamase-producing Gram-negative organisms
Rohit Bazaz et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection
Elizabeth B. Hirsch et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Bacteremia complicating gram-negative urinary tract infections: A population-based study
Majdi N. Al-Hasan et al.
JOURNAL OF INFECTION (2010)
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review
Matthew E. Falagas et al.
LANCET INFECTIOUS DISEASES (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy et al.
LANCET INFECTIOUS DISEASES (2010)
Urinary Tract Infection in Male General Practice Patients: Uropathogens and Antibiotic Susceptibility
J. J. Koeijers et al.
UROLOGY (2010)
National Healthcare Safety Network (NHSN) report: Data summary for 2006 through 2008, issued December 2009
Jonathan R. Edwards et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2009)
Changes in aac(6′)-Ib-cr Prevalence and Fluoroquinolone Resistance in Nosocomial Isolates of Escherichia coli Collected from 1991 through 2005
Gabriela Warburg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis
K. G. Naber et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Doripenem Monohydrate, A Broad-Spectrum Carbapenem Antibiotic
S. James Matthews et al.
CLINICAL THERAPEUTICS (2009)
Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
R. Maviglia et al.
CURRENT DRUG TARGETS (2009)
Therapeutic options for infections due to vancomycin-resistant enterococci
Jiun-Ling Wang et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Secular Trend and Risk Factors for Antimicrobial Resistance in Escherichia coli Isolates in Switzerland 1997-2007
L. Blaettler et al.
INFECTION (2009)
Antimicrobial Susceptibility of Bacteria Isolated from Urine Samples Obtained from Nursing Home Residents
Rituparna Das et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
The Newer Fluoroquinolones
Maureen K. Bolan
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2009)
CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin
Jesus Oteo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007
Majdi N. Al-Hasan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics
Katsumi Shigemura et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2009)
The Use of Carbapenems in the Treatment of Serious Infections
Robert P. Baughman
JOURNAL OF INTENSIVE CARE MEDICINE (2009)
Nitrofurantoin: the return of an old friend in the wake of growing resistance
James Kashanian et al.
BJU INTERNATIONAL (2008)
Fluoroquinolone resistance during 2000-2005: An observational study
Richard J. Ryan et al.
BMC INFECTIOUS DISEASES (2008)
Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: A first step to measure and improve care
H. S. Hermanides et al.
CLINICAL INFECTIOUS DISEASES (2008)
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis
David A. Talan et al.
CLINICAL INFECTIOUS DISEASES (2008)
Levofloxacin - A review of its use as a high-dose, short-course treatment for bacterial infection
Vanessa R. Anderson et al.
DRUGS (2008)
Risk factors for community-acquired urinary tract infection due to quinolone-resistant E-coli
R. Colodner et al.
INFECTION (2008)
Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli
Gary E. Stein et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2008)
Double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis
Janet Peterson et al.
UROLOGY (2008)
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-β-lactamase-producing Escherichia coli
Wolfgang A. Krueger et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Stenotrophomonas maltophilia:: Changing spectrum of a serious bacterial pathogen in patients with cancer
Amar Safdar et al.
CLINICAL INFECTIOUS DISEASES (2007)
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis
Howard A. Klausner et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Identification and pretherapy susceptibility of pathogens' in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the united states from November 2004 through April 2006
Janet Peterson et al.
CLINICAL THERAPEUTICS (2007)
Community-onset urinary tract infections: A population-based assessment
K. B. Laupland et al.
INFECTION (2007)
State of the art: imaging of renal infections
Jennifer Demertzis et al.
EMERGENCY RADIOLOGY (2007)
Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary
Johann D. D. Pitout et al.
EMERGING INFECTIOUS DISEASES (2007)
Comparative review of the carbapenems
George G. Zhanel et al.
DRUGS (2007)
The clinical impact of bacteremia in complicated acute pyelonephritis
Chih-Yang Hsu et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2006)
Are blood cultures necessary in the management of women with complicated pyelonephritis?
Yael Chen et al.
JOURNAL OF INFECTION (2006)
Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics Data from the PEP and PEAP-studies
Truls E. Bjerklund Johansen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Current challenges in the treatment of complicated urinary tract infections and prostatitis
FME Wagenlehner et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
A Robicsek et al.
NATURE MEDICINE (2006)
Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis
DA Talan et al.
JOURNAL OF UROLOGY (2004)
Newer carbapenems for urinary tract infections
T Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance
LG Miller et al.
MAYO CLINIC PROCEEDINGS (2004)
Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy
WG Wells et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Blood cultures for women with uncomplicated acute pyelonephritis:: Are they necessary?
M Velasco et al.
CLINICAL INFECTIOUS DISEASES (2003)
Does this woman have an acute uncomplicated urinary tract infection?
S Bent et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Comparison of test characteristics of urine dipstick and urinalysis at various test cutoff points
RL Lammers et al.
ANNALS OF EMERGENCY MEDICINE (2001)
Activity of levofloxacin and ciprofloxacin against urinary pathogens
L Drago et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)